| Writing group member |
Employment | Research grant | Other research support |
Speakers’ bureau/ honoraria |
Expert witness |
Ownership interest |
Consultant/ advisory board |
Other |
|---|---|---|---|---|---|---|---|---|
| Matthew A. Allison | University of California, San Diego | None | None | None | None | None | None | None |
| David G. Armstrong | Keck School of Medicine of USC Keck Medical Center of USC | NIH (This study is partially supported by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Award Number 1R01124789-01A1)†; NSF (This study is partially supported by NSF CNS Award Number 2052578)† | None | None | None | None | None | None |
| Philip P. Goodney | Dartmouth Hitchcock Medical Center | None | None | None | None | None | None | None |
| Naomi M. Hamburg | Boston University School of Medicine | None | None | None | None | None | Sanifit* | None |
| Lee Kirksey | The Cleveland Clinic | None | None | None | None | None | None | None |
| Kristie J. Lancaster | NYU Steinhardt | None | None | None | None | None | Council on Black Health* | None |
| Carlos I. Mena-Hurtado | Yale University School of Medicine | None | None | None | None | None | Abbott†; Cook†; Penumbra* | |
| Sanjay Misra | Mayo Clinic | None | Medtronic (consultant/research)*; NHLBI (R01 grant-HL098967)†; RMM (research funding)† | None | None | None | None | None |
| Diane J. Treat-Jacobson | University of Minnesota School of Nursing | NIH (PROVE trial site PI, COCOA trial site PI, INTERCEDE trial site PI)† | None | None | None | None | None | None |
| Khendi T. White Solaru | University Hospitals Cleveland Medical Center Harrington Heart and Vascular Institute | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.